LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR) & MiNK Therapeutics (NASDAQ:INKT) Critical Contrast
LadRx (OTCMKTS:CYTR – Get Rating) and MiNK Therapeutics (NASDAQ:INKT – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
LadRx（OTCMKTS: CYTR — 获取评级）和 minK Therapeutics（纳斯达克股票代码：INKT — 获取评级）都是小型医疗公司，但哪家企业更好？我们将根据两家企业的风险实力、估值、股息、机构所有权、分析师建议、收益和盈利能力对比这两家企业。
Earnings & Valuation
收益与估值
This table compares LadRx and MiNK Therapeutics' gross revenue, earnings per share and valuation.
该表比较了LadRx和minK Therapeutics的总收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| LadRx | N/A | N/A | -$6.70 million | ($0.15) | N/A |
| MiNK Therapeutics | N/A | N/A | -$30.21 million | ($0.78) | -2.71 |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| LadRx | 不适用 | 不适用 | -670 万美元 | (0.15 美元) | 不适用 |
| MinK 疗法 | 不适用 | 不适用 | -3,021 万美元 | (0.78 美元) | -2.71 |
MiNK Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.
MinK Therapeutics的交易市盈率低于LadRx，这表明它目前是这两只股票中更实惠的一只。
Profitability
盈利能力
This table compares LadRx and MiNK Therapeutics' net margins, return on equity and return on assets.
该表比较了LadRx和MinK Therapeutics的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| LadRx | N/A | -67.61% | -45.39% |
| MiNK Therapeutics | N/A | -168.94% | -78.30% |
| 净利润 | 股本回报率 | 资产回报率 | |
| LadRx | 不适用 | -67.61% | -45.39% |
| MinK 疗法 | 不适用 | -168.94% | -78.30% |
Risk & Volatility
风险与波动性
LadRx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of -0.66, suggesting that its stock price is 166% less volatile than the S&P 500.
LadRx的beta值为1.96，这表明其股价的波动性比标准普尔500指数高96％。相比之下，minK Therapeutics的beta值为-0.66，这表明其股价的波动性比标准普尔500指数低166％。
Analyst Recommendations
分析师建议
This is a breakdown of recent ratings and target prices for LadRx and MiNK Therapeutics, as provided by MarketBeat.
这是MarketBeat提供的LadRx和minK Therapeutics最近的评级和目标价格的明细。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LadRx | 0 | 0 | 0 | 0 | N/A |
| MiNK Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 卖出评级 | 持有评级 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| LadRx | 0 | 0 | 0 | 0 | 不适用 |
| MinK 疗法 | 0 | 0 | 1 | 0 | 3.00 |
MiNK Therapeutics has a consensus target price of $7.00, indicating a potential upside of 231.75%.
MinK Therapeutics的共识目标价格为7.00美元，表明潜在的上涨空间为231.75％。
Institutional & Insider Ownership
机构和内部所有权
0.1% of LadRx shares are held by institutional investors. Comparatively, 1.4% of MiNK Therapeutics shares are held by institutional investors. 12.8% of LadRx shares are held by company insiders. Comparatively, 13.2% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
0.1% 的LadRx股票由机构投资者持有。相比之下，1.4％的MinK Therapeutics股票由机构投资者持有。12.8％的LadRx股票由公司内部人士持有。相比之下，MinK Therapeutics的股票中有13.2％由公司内部人士持有。强大的机构所有权表明大型基金经理、对冲基金和捐赠基金认为一家公司有望实现长期增长。
Summary
摘要
LadRx beats MiNK Therapeutics on 6 of the 9 factors compared between the two stocks.
与两只股票相比，LadRx在9个因素中有6个击败了MinK Therapeutics。
About LadRx
关于 LadRx
(Get Rating)
（获取评级）
LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.
LadRx Corporation是一家生物制药公司，从事治疗癌症患者的疗法的发现和开发。该公司的先进药物偶联物阿多柔比星正在进行后期临床试验，是抗癌药物多柔比星的一种版本。其临床前疗法包括针对癌症的链接活化药物释放的7、8、9和10。该公司前身为CytrX Corporation，并于2022年9月更名为LadrX Corporation。LadRx Corporation 成立于 1985 年，总部位于加利福尼亚州洛杉矶。
About MiNK Therapeutics
关于 MinK Therapeut
(Get Rating)
（获取评级）
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
MinK Therapeutics, Inc. 是一家临床阶段的生物制药公司，从事用于治疗癌症和其他免疫介导疾病的同种异体、现成、不变的自然杀伤 T (inKT) 细胞疗法的发现、开发和商业化。其候选产品是 AGENT-797，这是一种现成的同种异体药物，用于 inkT 细胞疗法和各种骨髓瘤疾病的治疗，目前正处于 1 期临床试验。该公司前身为AgentUS Therapeutics, Inc.。minK Therapeutics, Inc. 成立于2017年，总部位于纽约州纽约。minK Therapeutics, Inc. 是Agenus Inc.的子公司。
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 LadRx 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收LadrX及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。